June 22, 2010 – Data from the FAST-PVI study, supported by Medtronic Inc., shows lab time using anatomically designed ablation catheters are more than one-third faster than traditional point-by-point focal ablation procedures in achieving pulmonary vein isolation (PVI).
PVI is the cornerstone catheter procedure to treat paroxysmal atrial fibrillation (PAF). The anatomically shaped Arctic Front Cardiac CryoAblation Catheter and advanced radiofrequency (RF) Pulmonary Vein Ablation Catheter (PVAC) allowed physicians to more efficiently isolate the pulmonary veins than do focal RF catheters. Acute PVI success rate for the anatomical catheters was 99 percent. The data were released at Cardiostim 2010, the 17th World Congress in Cardiac Electrophysiology and Cardiac Techniques.
The Arctic Front is approved in Europe to treat paroxysmal atrial fibrillation (AF); PVAC is approved in Europe to treat supraventricular tachycardia (SVT). Both catheters are under investigational use in the United States. Arctic Front is under U.S. Food and Drug Administration (FDA) review for paroxysmal AF and PVAC for the treatment of continuous AF.
“FAST-PVI is the first study quantifying procedure time efficiency improvements associated with the use of anatomically designed catheter ablation systems,” said Gunnar Klein, M.D., Ph.D., Hannover Medical School in Hannover, Germany. “The shorter and more predictable procedure times allow me to better manage lab time and treat more patients.”
The goal of catheter ablation is to isolate the pulmonary vein to stop the rapid beating of the upper heart chambers by ablating (or blocking) the conduction pathways that trigger atrial fibrillation (AF). Catheter ablation is a minimally invasive procedure that is recommended after commonly prescribed drugs have failed to achieve acceptable results in symptomatic patients. Previously, AF ablation procedures could only be performed with a time-consuming point-by-point focal ablation technique to create individual lesions to block AF conductivity. Now, anatomically shaped catheters can efficiently create lesions with fewer applications because they have been designed specifically for isolating the pulmonary vein.
November 18, 2024 
